Enhertu (fam-trastuzumab deruxtecan-nxki) received FDA regular approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
Norman Wolmark, chairman of the NSABP Foundation Inc., and group chair and contact principal investigator of NRG Oncology, received the 2024 American Surgical Association Medallion for Advancement of Surgical Care at the American Surgical Association’s 144th annual meeting in Washington, DC.
